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Abstract
Background: Narcolepsy with cataplexy (NC) is a disabling sleep disorder characterized by early loss of hypocretin neurons
that project to areas involved in the attention network. We characterized the executive control of attention in drug-free
patients with NC to determine whether the executive deficits observed in patients with NC are specific to the disease itself
or whether they reflect performance changes due to the severity of excessive daytime sleepiness.
Methodology: Twenty-two patients with NC compared to 22 patients with narcolepsy without cataplexy (NwC) matched for
age, gender, intellectual level, objective daytime sleepiness and number of sleep onset REM periods (SOREMPs) were
studied. Thirty-two matched healthy controls were included. All participants underwent a standardized interview,
completed questionnaires, and neuropsychological tests. All patients underwent a polysomnography followed by multiple
sleep latency tests (MSLT), with neuropsychological evaluation performed the same day between MSLT sessions.
Principal Findings: Irrespective of diagnosis, patients reported higher self-reported attentional complaints associated with
the intensity of depressive symptoms. Patients with NC performed slower and more variably on simple reaction time tasks
than patients with NwC, who did not differ from controls. Patients with NC and NwC generally performed slower, reacted
more variably, and made more errors than controls on executive functioning tests. Individual profile analyses showed a clear
heterogeneity of the severity of executive deficit. This severity was related to objective sleepiness, higher number of
SOREMPs on the MSLT, and lower intelligence quotient. The nature and severity of the executive deficits were unrelated to
NC and NwC diagnosis.
Conclusions: We demonstrated that drug-free patients with NC and NwC complained of attention deficit, with altered
executive control of attention being explained by the severity of objective sleepiness and global intellectual level. Further
studies are needed to explore whether medications that promote wakefulness can improve the executive functions in
narcolepsy.
Citation: Bayard S, Croisier Langenier M, Cochen De Cock V, Scholz S, Dauvilliers Y (2012) Executive Control of Attention in Narcolepsy. PLoS ONE 7(4): e33525.
doi:10.1371/journal.pone.0033525
Editor: Wing-ho Yung, The Chinese University of Hong Kong, Hong Kong
Received September 23, 2011; Accepted February 15, 2012; Published April 25, 2012
Copyright:  2012 Bayard et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Study financed by the Montpellier Teaching Hospital (AOI UF8190) at the Regional Delegation for Clinical Research and Innovation. The funders had no
role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: bayardsophie@yahoo.fr
Introduction
Narcolepsy with cataplexy (NC) is a rare disabling disorder
characterized by excessive daytime sleepiness (EDS), cataplexy,
and other dissociated manifestations of rapid eye movement
(REM) sleep phenomena such as sleep paralysis and hypnagogic
hallucinations [1]. Narcolepsy was further classified into narco-
lepsy with and without (NwC) cataplexy (ICSD2). Recent
pathophysiological studies have demonstrated that NC is caused
by the early loss of hypothalamus neurons that produce
hypocretin/orexin, a wakefulness-associated neurotransmitter that
can be measured in the cerebrospinal fluid (CSF) [1–4]. In
contrast, NwC is rarely caused by hypocretin deficiency, and
affects only 10–30% of patients, supporting the concept of
different pathogeneses in central hypersomnias [1–4].
NC significantly interferes with several aspects of daily life,
wielding negative social and professional impacts that may
considerably affect the quality of life [5–9]. Hence, patients with
NC frequently have problems at school and at home, and find it
difficult to obtain and maintain employment and to form
relationships [10,11]. Most of these behavioural difficulties may
be attributable to the integrity of the executive functions, including
distractibility, decision-making and organization problems, and
difficulties in making, carrying out, and adjusting plans [12].
Recent studies have reported clear interactions between EDS and
executive functioning [13]. Hypocretin has been reported as an
essential neural substratum for many types of motivated
behaviours [14]. To date, it remains unclear whether the
limitations noted in patients with NC are related to the severity
of EDS or are specific to NC, i.e., due to hypocretin deficiency.
Studies on cognitive functioning in central hypersomnia are
rare. They have generally addressed memory, attention areas and
decision-making, focusing on NC only [15–18]. Early findings
showed that patients with NC did not differ from healthy controls
on various executive tasks, such as working memory tests, set
shifting, planning or verbal fluency and complex verbal reasoning
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naı ¨ve patients with NC, but without any relationship to the
severity of objective daytime sleepiness [18]. Two other studies
stressed poor divided and flexibility performance in patients with
NC compared to healthy controls [18,22]. In sum, the objective
evidence for impairment in executive control of attention in NC is
contradictory. Furthermore, the performance of patients with NC
has never been compared to that of patients with other central
hypersomnias in order to determine the respective impact of
objective sleepiness and hypocretin deficiency on executive
performance.
Theoretical framework of executive control models have
stressed the complex relations existing between executive func-
tioning per se and other cognitive areas such as working memory
[23] and attention [24]. One comprehensive model identified
three independent executive components: (1) inhibition of pro-
ponent responses (‘‘Inhibition’’), (2) information updating and
monitoring (‘‘Updating’’), and (3) mental set shifting (‘‘Shifting’’)
[25].
We hypothesized that executive control of attention problems in
narcolepsy would be heterogeneous. One subgroup of patients
would have executive performances within normal limits while
others would display significant executive impairments. Further-
more, we hypothesized that the severity of objective sleepiness will
significantly contribute to the executive performances in patients
with narcolepsy, without major differences between patients with
and without cataplexy. The aims of this study were (1) to better
characterize the executive control of attention in drug-free patients
with narcolepsy-cataplexy in comparison to patients with narco-
lepsy without cataplexy, and to controls matched for sex, age and
intellectual level; and (2) to determine the impact of clinical and
polysomnographic variables on executive performances in narco-
lepsy.
Materials and Methods
Subjects
Subjects were 22 adult patients with NC (12 males, aged 16–74
years) and 22 adult patients with NwC (14 males, aged 15–65
years) matched for age, gender, intellectual level, objective daytime
sleepiness, and number of SOREMPs. Seven patients with NC
were treatment-naı ¨ve and 15 were drug-free (no psychostimulants
or anticataplectic medications) for at least one month prior to
evaluation. All patients with NwC were drug-naı ¨ve. Narcolepsy
diagnosis met the ICSD-2 criteria [26] (The International
Classification of Sleep Disorders, 2005): presence of EDS, mean
sleep latency of less than 8 minutes, and at least two sleep onset
REM periods (SOREMP) during the multiple sleep latency test
(MSLT). All patients with NC had clear-cut cataplexy and were
HLA DQB1*0602 positive. Patients with NwC had no clinical
evidence for cataplexy. HLA DQ typing was performed in 19
patients with NwC with 6 HLA DQB1*0602 positive (30%). No
patients had any current psychiatric disorder based on the DSM-
IV criteria [27] or associated neurological disorders. Of the 11
patients who had had a lumbar puncture, five patients with NC
had undetectable CSF hypocretin-1 levels and six patients with
NwC had normal levels (.200 pg/ml).
Thirty-two healthy age-, gender-, and intellectual level-matched
controls (15 males, aged 21–53 years) were recruited from the
community. All healthy controls were community-dwelling adults
living in Montpellier, France, recruited through local associative
networks. The inclusion criteria for controls were the ability to
understand and give informed consent, no history of neurological
or psychiatric disease, and no intake of medications known to
influence sleep or cognition. All controls scored ,10 on the
Epworth Sleepiness Scale (ESS) [28]. HLA typing was not
available for controls.
All patients and controls gave their informed written consent to
take part in the whole study which was approved by the Local
Ethics Committee (University Hospital, Montpellier, France).
Additional written consent was obtained from the parents of
participants under the age of 18.
Polysomnography Recordings
All patients (n=44) underwent one night of PSG recording
followed by the MSLT the next day, consisting of five naps
scheduled at 2-hour intervals starting at 9:00 a.m. [29]. The PSG
investigation included measures of sleep, respiratory events,
cortical arousals, and periodic leg movements, scored according
to standard criteria [30]. Subjects with a respiratory event index
(apnea index+hypopnea index) .10 were excluded from the study.
Clinical and Neuropsychological Evaluation
All participants underwent a standardized face-to-face clinical
interview and were asked to complete questionnaires, including
the 21-item Beck Depression Inventory-II [31] and the French
adaptation of the National Adult Reading Test, fNART [32] to
estimate premorbid intelligence quotient (IQ). Patients were all
tested after the first MSLT scheduled at 9:00 AM.
Self-Evaluation Attention Questionnaire (QAA) [33]. All
subjects completed the QAA. It contains 50 questions divided into
seven sections representing different dimensions of concrete
activities and situations of daily life: Reading, Conversation,
Television, Activities, Distractions, Fatigue, and Driving. Each
section includes from 4 to 11 questions. For each question,
participants rate on a 6-point scale (from never=1 to always=6)
the frequency with which they encounter difficulties in a particular
situation. A single score per section and a total score are computed
to assess the different complaints concerning daily life activities.
Executive function assessment. We used a computer-based
neuropsychological battery, Zimmermann and Fimm’s attention
test battery (Testbatterie zur Aufmerksamkeitspru ¨fung – TAP)
[34], to evaluate attention. This well-validated test battery
provides normative data for adults. The tasks consist of simple,
easily distinguishable stimuli to which the patient’s motor response
is recorded. A button box with millisecond accuracy was used to
capture reaction times (RTs) and record responses (false alarms
and/or omissions). Based on Miyake and co-workers’ [25]
inventory of executive functioning, three subscales of the TAP
were used and administered in random order: the 2-Back Task
(Updating), the Go/No-Go Task (Inhibition), and the Flexibility Task
(Shifting). A fourth task in the TAP, the Tonic/Phasic Alertness
Task, was systematically administered at the beginning (Time 1)
and end (Time 2) of the evaluation to obtain a behavioural control
of fatigability. Each task did not exceed 7 minutes, without any
pause proposed in between.
Tonic and Phasic alertness: This test was administered in two
conditions: tonic and phasic alertness. It was assessed by simple
and forewarned reaction time (RT). In phasic condition, the visual
target was preceded by a tone. In tonic alertness, participants had
to press a button when a visual target (cross) appeared on a screen.
2-Back Task (Updating): Participants were presented with a series
of digits (ranging from 1 to 9) in a specific sequence. They were
instructed to compare each digit with the digit presented two
cycles previously and respond by pressing a key.
Go/No-Go Task (Inhibition): In this task, a ‘‘x’’ and a ‘‘+’’ were
presented. Participants were asked to detect only the cross.
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presented on the left or right side of the screen. Participants had to
indicate the side where the digit was presented using a right or left
button press response. On trial n+1, participants were required to
detect the side where the letter appeared. Across successive trials,
participants had to shift from letter to digit location, and vice
versa.
Statistical Methods
Data were examined for normal distribution and homogene-
ity of variance. As distributions of QAA measures were skewed,
logarithmic transformations were performed using log10X (as
recommended by Tabachnik and Fidell), with skewness values
being within the acceptable range. For TAP tasks, median RTs,
standard deviations (SDs) of RTs, and number of errors (false
alarms and omissions) were used as primary measures. PSG and
MSLT recording data were scored blinded to the groups and
executive performances. Group differences in demographic data,
clinical variables, and scale scores were analyzed with one-way
between-groups analysis of variance (ANOVA) and Student’s t-
tests for independent samples for continuous variables, the
Mann-Whitney test for ordinal data, and the x
2 test for
categorical variables. A 262 mixed-factorial repeated measures
ANOVA (MANOVA) with group as a between-subjects factor
and phasic/tonic alertness tasks (repeated at Time 1 and 2) as
a within-subjects factor was performed, using median RTs and
SDs for Tonic and Phasic condition as dependent variables. In
order to determine executive deficits, data on each executive
TAP task were also compared to normative data for RTs, SDs
of RTs, and/or errors and omissions, taking into account age
and education level [31]. Impairment in executive tasks was
defined as a score below the 10th percentile of the norm. The
number of impaired executive tasks could therefore vary from
0 to 3. The following variables were considered to determine
executive performance: group, estimated intelligence quotient,
general slowing at TAP, depressive symptom intensity, objective
and subjective sleepiness, SOREMPs at MSLT, sleep efficiency,
and SWS and REM percentages. Statistical analyses were
performed with SPSS version 12.0 for Windows (Chicago,
SPSS, Inc.). The level of significance was a , 0.05.
Results
Demographic, clinical, biological, and
polysomnographical data
Chi-squared analysis revealed no differences between the two
groups of patients and healthy controls in either age or
intellectual level. One-way ANOVA indicated a main Group
effect for the BDI-II and ESS, with narcoleptic patients
reporting higher subjective complaints of sleepiness and higher
intensity of depressive symptoms than controls. Differences were
also observed in the narcoleptic group with higher BDI-II and
ESS scores in patients with NC compared to patients with NwC
(respectively, p=0.049 and p=0.039).
Patients with NC had more frequent sleep paralysis (68%)
and hypnagogic hallucinations (77%) than patients with NwC
(respectively 22% and 22%), with none in controls. No
difference was noted between the NC and NwC groups in
age at disease onset. The NC and NwC groups were matched
for mean sleep latency and number of SOREMPs on the
MSLT. Patients with NC had lower sleep efficiency, sleep and
REM sleep latencies than patients with NwC. They also had
shorter REM sleep latency (Table 1).
Self-Evaluation Attention Questionnaire
Significant correlations were found between sections of the
QAA and the BDI-II scale in the control group and in patients
with narcolepsy. Group comparison analyses on the QAA were
thus performed with the BDI-II score as covariate. Figure 1
displays the scores obtained by patients with narcolepsy (with
and without cataplexy, N=44) and healthy controls (N=32) on
each section of the QAA and total scores. Patients with NC and
NwC reported higher attentional complaints than controls
excepted for Reading, Distractions and Driving sections.
Bonferroni post hoc tests indicated no significant difference
between patients with NC and NwC (all p-values.0.20). We
found no association between the attentional complaint level,
demographical, clinical and polysomnographical variables.
Executive Functions Assessment
Group comparisons: Tonic and Phasic alertness. The
analysis of Tonic alertness median and SDs of RTs showed
a significant main effect of Group [respectively: F(2,72)=14.4,
p,0.001, g
2=0.18; F(2,72)=11.7, p,0.001, g
2=0.24] and
Time [respectively: F(2,72)=5.3, p=0.024, g
2=0.06;
F(2,72)=10.6, p=0.002, g
2=0.12], and a significant Group x
Time interaction [respectively: F(2,72)=8.05, p=0.001;
F(2,72)=6.4, p=0.003, g
2=0.15] (Figure 2A). Post hoc
multiple comparisons with Bonferroni corrections indicated
that patients with NC showed significantly slower RTs and
more variable SDs of RTs compared to healthy controls (all p-
values,0.001) and patients with NwC (all p-values,0.01),
whereas patients with NwC did not differ from controls (all p-
values .0.50). In addition, patients with NC were more affected
by testing session than patients with NwC (all p-values,0.001)
and controls (all p-values,0.001), with slower and more variable
RTs at Time 2. The same results pattern was observed for
Phasic alertness median and SDs of RTs, with significant effects
of Group and Time and a significant Group x Time interaction
(Figure 2B). We may add that none of participants fell asleep
during the testing session.
Updating, inhibition, and flexibility. An ANOVA
performed on median of RTs indicated a main Group effect for
all executive tasks [2-Back: F(2,72)=3.4, p=0.038, g
2=0.08; Go/
No-Go: F(2,72)=9.9, p,0.001, g
2=0.23; Flexibility:
F(2,72)=13.3, p=0.001, g
2=0.27] (Figure 3A). Post hoc
analyses revealed that patients with NC were slower than
healthy controls on all executive tasks (all p-values ,0.05) and
slower than patients with NwC on the Go/No-Go (p,0.001) and
Flexibility (p=0.046) tasks. The ANOVA conducted on SDs of
RTs showed a Group effect for the 2-Back [F(2,72)=4.3,
p=0.016, g
2=0.11] and Flexibility [F(2,72)=8.1, p=0.001,
g
2=0.18] tasks (Figure 3B). Contrast analyses showed that
patients with NC had more variability in performance than
controls on the 2-Back (P=0.017) and Flexibility (p,0.001) tasks.
Patients with NwC showed more variable performance than
controls on the Flexibility task (p=0.042). Kruskal Wallis tests
performed on error rates revealed a main Group effect for the 2-
Back (Z=12.1, p=0.002) and Flexibility (Z=11.3, p=0.003) tasks
(Figure 3C). Contrast analyses showed that patients with NC were
less accurate than controls (2-Back, p=0.01; Flexibility,
p=0.048).Patients with NwC made also more errors than
controls (2-Back, p=0.024; Flexibility, p=0.001). No significant
associations were found between BDI-II, ESS scores, Tonic and
Phasic alertness and complex executive performances in the whole
sample and in patients with narcolepsy only.
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Patients and controls were compared to the normative data on
the four TAP tasks, taking into account age and education level
[34].
Tonic and Phasic alertness. Most of patients showed
normal performance at Time 1, but not at Time 2 with both
Phasic (n=11) and Tonic (n=10) alertness impairment. In
contrast, two controls only had abnormal performance on Phasic
(n=1) and Tonic (n=1) alertness. Contrast analyses indicated that
patients with NC were slower than patients with NwC on the
Phasic (x
2=9.2, p=0.002) and Tonic (x
2=5.6, p=0.018) alertness
tasks. Patients with the most Phasic and Tonic alertness
impairment at Time 2 had the shortest MSLT latency
(respectively, Z=22.08, p=0.036; Z=21.8, p=0.05).
Updating, inhibition, and flexibility. The number of
altered executive tasks (updating, inhibition, and flexibility)
differed between patients with NC, NwC, and controls
(x
2=37.0, p,0.001) (Figure 4). Our controls performed
normally on 88% of the TAP tasks, in contrast to patients with
NC (23%) and NwC (35%). However, no between patient group
differences were noted on the number and type of impaired
executive tasks (Figure 4).
Analyses of Correlates
To study the correlates of the deficit in complex executive
performances, patients with narcolepsy (N=44) were split into two
groups, those with at least one executive deficit (n=32) and those
without (n=12). Patients with altered performance had shorter
MSLT latency (Z=22.71, p=0.006), higher SOREMPs
(Z=22.40, p=0.019), and lower estimated intellectual level
(Z=22.28, p=0.021) than patients without. The number of
SOREMPs was negatively correlated with MSLT latencies
(r=20.32; p=0.01) in patients with narcolepsy. Interestingly, no
between-group differences on executive deficit exist regarding the
Phasic/Tonic Alertness tasks at Times 1 and 2, and the QAA
evaluation.
Discussion
This study was the first to investigate the executive control of
attention in a sizeable group of drug-free patients with NC
compared to patients with NwC and healthy controls. The main
question of the present study was whether the observed executive
deficits in narcolepsy are specific to its pathophysiology or whether
they reflect performance changes due to the severity of objective
Table 1. Demographic, clinical, and polysomnographic characteristics of patients with narcolepsy-cataplexy, narcolepsy without
cataplexy, and healthy controls.
Narcolepsy
with cataplexy
N=22
Narcolepsy without
cataplexy N=22
Healthy controls
N=32 p
Demographic and clinical data
Age 36.2615.2 29.14612.5 30.2268.3 0.19
a
Men/Women 12/10 14/8 15/17 0.95
b
Estimated intelligence quotient (IQ) 108.366.3 107.068.3 110.265.1 0.24
a
Body mass index 24.563.9 23.564.0 22.762.4 0.19
a
Beck Depression Inventory 16.269.7 9.6610.9 3.963.7 ,0.001
a,d,e
Age at onset, years 22.3610.3 20.369.6 - 0.50
a
Sleep paralysis,% 68 22 - 0.006
b
Hypnagogic hallucinations,% 77 22 - 0.001
b
Epworth Sleepiness Scale 18.563.0 16.064.3 5.562.4 ,0.001
a,e,f
Nocturnal sleep parameters
Sleep latency 9.5610.7 31.7642.1 ,0.001
c
REM latency 30.8643.2 54.1631.1 0.03
c
Total sleep time 428.1648.9 430.8666.3 0.87
c
Sleep efficiency 84.368.6 90.465.3 0.007
c
% SWS 19.565.4 21.366.3 0.31
c
% REM 23.364.7 23.066.5 0.86
c
Apnea/hypopnea index 2.763.1 1.662.3 0.33
c
Diurnal sleep parameters
Sleep latency at MSLT{ 5.261.9 5.961.4 0.13
c
SOREMPs, number{ 3.761.0 3.360.1 0.18
c
Data are presented as means6standard deviations. PSG refers to Polysomnography; MSLT, Multiple Sleep Latency Test; SOREMPs, Sleep onset Rapid Eye Movement
Periods; REM, Rapid Eye Movement; SWS, Slow Wave Sleep. SaO2: Oxygen saturation.
aOne-way ANOVA.
bChi-square test.
cMann-Whitney test.
dNarcolepsy/Cataplexy vs. Controls.
eNarcolepsy/Cataplexy vs. Narcolepsy without Cataplexy.
fNarcolepsy vs. Controls.
gNarcolepsy without Cataplexy vs. Controls.
doi:10.1371/journal.pone.0033525.t001
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PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e33525Figure 1. Score obtained on the 7 sections of the Self-Evaluation Attention Questionnaire (QAA) for patients with narcolepsy and
for healthy controls. Mean (6SEM) are given.
doi:10.1371/journal.pone.0033525.g001
Figure 2. TAP median (left panel) and standard deviation (right panel) reaction times across Tonic (A) and Phasic (B) Task for
patients with narcolepsy and for healthy controls. The Tonic/Phasic Task was systematically administered at the beginning (Time 1) and end
(Time 2) of the evaluation. Means (6SEM) are given. [Group
a, Time
b, Group x Time
c effects: all p-values,0.001]
doi:10.1371/journal.pone.0033525.g002
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matched for MSLT latencies, we aimed to control for the influence
of sleepiness on executive performance in the patient groups.
NC is characterized by loss of hypocretin-containing neurons
with widespread projections throughout the brain, including
regions involved in the executive network [35,36]. Recent studies
have reported that the hypocretin system increases emotion-
related behavioural responses [14]. In contrast, the large majority
of patients with NwC (70–90%) had normal CSF hypocretin1-
levels [4,9,37,38]. We found in the present study that, compared to
controls, patients with narcolepsy reported higher attentional
complaints, without any difference between patients with NC and
NwC. Patients with NC were slower and more variable on simple
reaction time tasks, especially when performed the second time,
compared to patients with NwC, without between NwC and
control differences. Regarding the executive functioning, patients
with narcolepsy generally performed slower, reacted more
variably, and made more errors than controls, showing a clear
heterogeneity of the severity of updating, inhibition, and flexibility
performances. The nature and severity of the executive deficits
were unrelated to the diagnosis of NC and NwC, and therefore
unrelated to hypocretin deficiency per se, but rather to objective
sleepiness, higher number of SOREMPs, and lower intellectual
quotient. Altogether, our results suggest that patients with NC with
hypocretin deficiency had low performances on both alertness and
complex executive tasks. In contrast, the unyet-established
Figure 3. TAP median reaction times (A), standard deviation reaction times (B) and errors (C) for patients with narcolepsy and for
healthy controls. Means (6 SEM) are given.
doi:10.1371/journal.pone.0033525.g003
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cognitive slowing on simple reaction time but may alter
performances on tasks requiring higher cognitive demand.
Few studies have addressed objective cognitive changes in
association with narcolepsy, and the results are contradictory [18–
22]. Several methodological aspects specifically related to the
executive functioning evaluation could explain these discrepancies.
The first is that a single task may be inadequate to capture
complex executive disturbances [12]. The second is related to the
overlapping between measures of intellectual level and executive
functioning [39]. Third, although some studies have reported
anatomic differences in attentional networks for vigilance and
executive functions, there is clear evidence that these networks
interact [13]. Finally, the few studies that have addressed executive
changes in association with narcolepsy included small clinical
samples of patients with mixed conditions (narcolepsy with and
without cataplexy, and both drug-naı ¨ve and medicated patients),
such that cognitive problems may have been underestimated
[18,22,40].
This study reported for the first time an individual approach to
the executive control of attention in narcolepsy. In relation to the
idea of the executive control of attention as a non-unitary concept,
we decided to assess executive functioning in patients and controls
using a fractionated approach based on a seminal cognitive study
[25].
We noted that estimated intellectual level was related to the
severity of executive TAP task impairments in patients with NC
and NwC. Although accurate analysis of executive performance
requires knowledge of individual performance on intelligence
measures, most cognitive studies in narcolepsy have not
controlled for this variable [19,22]. Performance on executive
tasks in patients with central hypersomnias requires careful
analysis and interpretation [41]. Alertness refers to the intrinsic
arousal that fluctuates on the order of minutes to hours, being
intimately involved in sustaining attention but also in the
cognitive tone required to perform the complex executive
control [42,43]. Hence, experimental sleep deprivation studies in
healthy controls had wide ranging effects on brain functioning,
affecting multiple, distinct components of cognition but
especially the cognitive processes mediated by the prefrontal
cortex, thereby degrading both attentional arousal and higher-
order cognitive functions, such as executive control of attention
[44,45]. As patients with central hypersomnia had reduced
arousal and vigilance in executive processes, the effects of
alertness/sleepiness should always be controlled for in assessing
the executive control of attention.
Two limitations in our study need to be addressed. First, CSF
hypocretin-1 level was determined in only five patients with NC
and six patients with NwC. In future, it would be useful to relate
the CSF hypocretin-1 level of patients with narcolepsy (with and
without cataplexy) to their executive performance. Secondly, the
sample size is relatively low (22 patients with NC and 22 with
NwC compared to 32 age-, gender-, and intellectual level-matched
controls), although sufficient to demonstrate significant reduced
performance on executive control attention tasks.
In sum, we demonstrated that drug-free patients with NC had
low performances on both alertness and executive tasks, in
contrast to patients with NwC with altered results only on tasks
requiring higher cognitive demand. The altered executive control
of attention is clearly heterogeneous in narcolepsy, being somehow
independent of the hypocretin deficiency per se, but mostly
explained by the severity of objective sleepiness and global
intellectual level. Further studies are needed to explore whether
medications that promote wakefulness can improve the executive
functions in narcolepsy.
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Figure 4. Rate of participants showing impairments in none, 1, 2, and 3 executive TAP tasks and in the nature of the executive
deficit.
doi:10.1371/journal.pone.0033525.g004
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